Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNRNP200 | O75643 | 3/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | SLC8A1 | P32418 | 7/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857178 | 0.94 | SNRNP200 (0.48) | SNRNP200SLC8A1 | |
| SCHEMBL16857317 | 0.91 | SNRNP200 (0.47) | SNRNP200SLC8A1 | |
| SCHEMBL16857237 | 0.91 | SNRNP200 (0.51) | SNRNP200 | |
| SCHEMBL16857295 | 0.91 | SNRNP200 (0.50) | SNRNP200NTRK1MDM2 | |
| SCHEMBL16857094 | 0.90 | SNRNP200 (0.50) | SNRNP200IP6K1 | |
| SCHEMBL16856788 | 0.90 | SNRNP200 (0.47) | SNRNP200 | |
| SCHEMBL16856888 | 0.90 | SNRNP200 (0.52) | SNRNP200IP6K1 | |
| SCHEMBL16856972 | 0.90 | SNRNP200 (0.48) | SNRNP200NTRK1 | |
| SCHEMBL16857149 | 0.88 | SNRNP200 (0.47) | SNRNP200NTRK1 | |
| SCHEMBL16857452 | 0.88 | SNRNP200 (0.52) | SNRNP200 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2889291-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299188-A1 | HETEROCYCLIC COMPOUND | PTGIS, LIPG, FEN1 | SNRNP200 3216/4885NTRK1 4847/4885SLC8A1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.